Log in

NYSE:EBS - Emergent Biosolutions Stock Price, Forecast & News

$53.32
-0.68 (-1.26 %)
(As of 12/12/2019 01:09 AM ET)
Today's Range
$53.06
Now: $53.32
$54.83
50-Day Range
$51.27
MA: $54.92
$59.06
52-Week Range
$39.11
Now: $53.32
$68.30
Volume286,611 shs
Average Volume438,536 shs
Market Capitalization$2.75 billion
P/E Ratio22.88
Dividend YieldN/A
Beta1.5
Emergent BioSolutions Inc, a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats (PHTs). Its products address PHTs, including chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travelers' diseases; and opioids. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
CUSIP29089Q10
Phone240-631-3200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$782.40 million
Cash Flow$3.46 per share
Book Value$19.84 per share

Profitability

Net Income$62.70 million

Miscellaneous

Employees1,705
Market Cap$2.75 billion
Next Earnings Date2/20/2020 (Estimated)
OptionableOptionable

Receive EBS News and Ratings via Email

Sign-up to receive the latest news and ratings for EBS and its competitors with MarketBeat's FREE daily newsletter.


Emergent Biosolutions (NYSE:EBS) Frequently Asked Questions

What is Emergent Biosolutions' stock symbol?

Emergent Biosolutions trades on the New York Stock Exchange (NYSE) under the ticker symbol "EBS."

How will Emergent Biosolutions' stock buyback program work?

Emergent Biosolutions declared that its board has initiated a stock buyback program on Friday, March 23rd 2018, which allows the company to repurchase $50,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to buy shares of its stock through open market purchases. Stock repurchase programs are usually a sign that the company's board believes its stock is undervalued.

How were Emergent Biosolutions' earnings last quarter?

Emergent Biosolutions Inc (NYSE:EBS) posted its quarterly earnings results on Wednesday, November, 6th. The biopharmaceutical company reported $1.21 EPS for the quarter, topping the consensus estimate of $0.63 by $0.58. The biopharmaceutical company earned $311.80 million during the quarter, compared to the consensus estimate of $289.16 million. Emergent Biosolutions had a return on equity of 10.05% and a net margin of 0.42%. The company's revenue for the quarter was up 79.6% on a year-over-year basis. During the same period last year, the firm earned $0.55 earnings per share. View Emergent Biosolutions' Earnings History.

When is Emergent Biosolutions' next earnings date?

Emergent Biosolutions is scheduled to release their next quarterly earnings announcement on Thursday, February 20th 2020. View Earnings Estimates for Emergent Biosolutions.

What price target have analysts set for EBS?

6 analysts have issued twelve-month price targets for Emergent Biosolutions' shares. Their forecasts range from $64.00 to $75.00. On average, they expect Emergent Biosolutions' stock price to reach $69.00 in the next year. This suggests a possible upside of 29.4% from the stock's current price. View Analyst Price Targets for Emergent Biosolutions.

What is the consensus analysts' recommendation for Emergent Biosolutions?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Emergent Biosolutions in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Emergent Biosolutions.

What are Wall Street analysts saying about Emergent Biosolutions stock?

Here are some recent quotes from research analysts about Emergent Biosolutions stock:
  • 1. Cantor Fitzgerald analysts commented, ". Post 1Q19, we reiterate our Overweight rating and our 12- month price target of $75. EBS continues to be the leader in the biodefense field, and the acquisition of Adapt and PaxVax leverage the company’s historical expertise, while further diversifying revenue away from BioThrax. We continue to believe the company’s business is a lot more durable than the Street is giving it credit for, and we expect Emergent to extend a number of its current contracts beyond current estimates, as well as bring some significant pipeline product to market over time. Emergent does not have the risk of commercial insurance reimbursement or payer pricing pressures on the majority of its portfolio." (5/2/2019)
  • 2. According to Zacks Investment Research, "Emergent BioSolutions' recent acquisitions of PaxVax and Adapt Pharma have expanded the company’s presence in the public health threats market. Its anthrax vaccine, NuThrax’s regulatory application is under review, with a decision expected in the first half of 2019. We are positive on Emergent’s spin-off of its biosciences business into a separate publicly traded company as it resulted in reduction of the cost structure. Notably, the company derives majority of its revenues from BioThrax sales. Hence, its sole dependence on BioThrax for revenues is a headwind. Moreover, Emergent depends on certain single-source suppliers for key materials and services, which are necessary for manufacturing BioThrax. This, in turn, raises a concern. Shares of the company have underperformed the industry so far this year. Estimates have narrowed ahead of Q1 earnings. Emergent has a mixed record of earnings surprises in the recent quarters." (4/8/2019)

Has Emergent Biosolutions been receiving favorable news coverage?

Media headlines about EBS stock have trended negative this week, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Emergent Biosolutions earned a news sentiment score of -3.0 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Emergent Biosolutions.

Are investors shorting Emergent Biosolutions?

Emergent Biosolutions saw a decrease in short interest in October. As of October 31st, there was short interest totalling 2,310,000 shares, a decrease of 14.1% from the September 30th total of 2,690,000 shares. Based on an average trading volume of 427,200 shares, the short-interest ratio is presently 5.4 days. Approximately 5.4% of the company's stock are sold short. View Emergent Biosolutions' Current Options Chain.

Who are some of Emergent Biosolutions' key competitors?

What other stocks do shareholders of Emergent Biosolutions own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Emergent Biosolutions investors own include Mercadolibre (MELI), Global Payments (GPN), Broadcom (AVGO), Netflix (NFLX), NXP Semiconductors (NXPI), NVIDIA (NVDA), CalAmp (CAMP), Gentherm (THRM), Activision Blizzard (ATVI) and Intel (INTC).

Who are Emergent Biosolutions' key executives?

Emergent Biosolutions' management team includes the folowing people:
  • Mr. Fuad El-Hibri, Founder & Exec. Chairman (Age 61)
  • Mr. Robert G. Kramer Sr., CEO, Pres & Director (Age 62)
  • Mr. Richard S. Lindahl, Exec. VP, CFO & Treasurer (Age 55)
  • Mr. Atul Saran, Exec. VP of Corp. Devel., Gen. Counsel & Corp. Sec. (Age 46)
  • Mr. Adam R. Havey, Exec. VP of Bus. Operations (Age 48)

Who are Emergent Biosolutions' major shareholders?

Emergent Biosolutions' stock is owned by many different of retail and institutional investors. Top institutional shareholders include State Street Corp (3.58%), Rice Hall James & Associates LLC (2.38%), Vaughan Nelson Investment Management L.P. (1.31%), Fisher Asset Management LLC (1.28%), Voya Investment Management LLC (0.76%) and Millennium Management LLC (0.73%). Company insiders that own Emergent Biosolutions stock include Adam Havey, Daniel Abdun-Nabi, Fuad El-Hibri, George A Joulwan, Jerome M Hauer, Kathryn C Zoon, Ronald Richard and Sue Bailey. View Institutional Ownership Trends for Emergent Biosolutions.

Which major investors are selling Emergent Biosolutions stock?

EBS stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Man Group plc, Voya Investment Management LLC, Squarepoint Ops LLC, Strs Ohio, Consolidated Investment Group LLC, Russell Investments Group Ltd. and Peregrine Capital Management LLC. Company insiders that have sold Emergent Biosolutions company stock in the last year include Adam Havey, Daniel Abdun-Nabi, Fuad El-Hibri and Kathryn C Zoon. View Insider Buying and Selling for Emergent Biosolutions.

Which major investors are buying Emergent Biosolutions stock?

EBS stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, Tygh Capital Management Inc., Vaughan Nelson Investment Management L.P., State of New Jersey Common Pension Fund D, California Public Employees Retirement System, First Trust Advisors LP, Boston Advisors LLC and Rice Hall James & Associates LLC. View Insider Buying and Selling for Emergent Biosolutions.

How do I buy shares of Emergent Biosolutions?

Shares of EBS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Emergent Biosolutions' stock price today?

One share of EBS stock can currently be purchased for approximately $53.32.

How big of a company is Emergent Biosolutions?

Emergent Biosolutions has a market capitalization of $2.75 billion and generates $782.40 million in revenue each year. The biopharmaceutical company earns $62.70 million in net income (profit) each year or $2.33 on an earnings per share basis. Emergent Biosolutions employs 1,705 workers across the globe.View Additional Information About Emergent Biosolutions.

What is Emergent Biosolutions' official website?

The official website for Emergent Biosolutions is http://www.emergentbiosolutions.com/.

How can I contact Emergent Biosolutions?

Emergent Biosolutions' mailing address is 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879. The biopharmaceutical company can be reached via phone at 240-631-3200 or via email at [email protected]


MarketBeat Community Rating for Emergent Biosolutions (NYSE EBS)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  366 (Vote Outperform)
Underperform Votes:  318 (Vote Underperform)
Total Votes:  684
MarketBeat's community ratings are surveys of what our community members think about Emergent Biosolutions and other stocks. Vote "Outperform" if you believe EBS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EBS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/12/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel